4//SEC Filing
Ahrens Brenton Karl 4
Accession 0000899243-22-031603
CIK 0001659323other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 6:00 PM ET
Size
11.5 KB
Accession
0000899243-22-031603
Insider Transaction Report
Form 4
Ahrens Brenton Karl
Director
Transactions
- Sale
Ordinary Shares
2022-09-19$1.77/sh−15,000$26,478→ 7,246 total(indirect: See Footnote) - Sale
Ordinary Shares
2022-09-20$1.78/sh−7,246$12,910→ 0 total(indirect: See Footnote) - Sale
Ordinary Shares
2022-09-16$1.90/sh−15,000$28,542→ 22,246 total(indirect: See Footnote)
Holdings
- 410
Ordinary Shares
Footnotes (5)
- [F1]The number of Ordinary Shares described herein reflect a 15:1 reverse stock split by the Issuer which became effective August 17, 2022.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 - $2.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 - $1.81, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Iterum Therapeutics plc
CIK 0001659323
Entity typeother
Related Parties
1- filerCIK 0001322927
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 6:00 PM ET
- Size
- 11.5 KB